文献速递重症综合管理与镇静镇痛儿科与产科急症

PICU中β-内酰胺类治疗药物管理

β-lactam Therapeutic Drug Management in the PICU.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论82例PICU患儿中95%未达β-内酰胺类药效学目标,感染队列23例经治疗药物管理后均达微生物应答,95.7%达临床应答,作者认为该管理可能是有价值的干预。

该研究为电子病历回顾,纳入2014年9月1日至2017年5月31日费城一家189张床位的独立儿童三级教学医院PICU中脓毒症及接受体外膜氧合或连续性肾脏替代治疗并接受常规β-内酰胺类治疗药物管理的患儿。总队列82例,感染队列23例,共248份治疗药物管理分析样本,中位年龄1岁(范围4天至18岁),平均体重19.7±22.3 kg(范围2.7-116 kg)。78/82例(95%)未达主要药效学终点,即抗感染浓度低于治疗水平。感染队列23例均达微生物应答,22/23例(95.7%)达临床应答。作者认为β-内酰胺类治疗药物管理可能是优化抗感染药代动力学和药效学暴露的有价值干预,并提示需在特定儿科人群及更大儿科队列中进一步研究。

要点

  • PICU患儿按现行儿童剂量推荐给药时,78/82例(95%)β-内酰胺类浓度低于治疗水平,未达主要药效学终点。
  • 感染队列23例中,22/23例(95.7%)达临床应答,全部达微生物应答。
  • 总队列82例中23例(28%)从正常无菌部位培养出明确病原体。
  • 作者认为β-内酰胺类治疗药物管理可能是优化抗感染药代动力学和药效学暴露的有价值干预。
  • 作者提示需在特定儿科人群及更大儿科队列中进一步研究β-内酰胺类治疗药物管理与临床结局的关系。

适用人群与场景

  • 2014年9月1日至2017年5月31日入住费城一家189张床位的独立儿童三级教学医院PICU的脓毒症患儿,以及接受体外膜氧合或连续性肾脏替代治疗并接受常规β-内酰胺类治疗药物管理的患儿。

研究设计与关键结果

  • 研究类型为电子病历回顾,总队列82例,感染队列23例,共248份治疗药物管理分析样本。
  • 中位年龄1岁(范围4天至18岁),平均体重19.7±22.3 kg(范围2.7-116 kg)。
  • 23/82例(28%)从正常无菌部位培养出明确病原体。
  • 78/82例(95%)抗感染浓度低于治疗水平,未达主要药效学终点。
  • 感染队列23例均达微生物应答,22/23例(95.7%)达临床应答。

证据类型、等级与局限

  • 证据类型为电子病历回顾。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为β-内酰胺类治疗药物管理可能是优化抗感染药代动力学和药效学暴露的有价值干预。
  • 作者提示需在特定儿科人群及更大儿科队列中进一步研究β-内酰胺类治疗药物管理与临床结局的关系。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine whether contemporary β-lactam anti-infective dosing recommendations in critically ill children achieve concentrations associated with maximal anti-infective activity. The secondary objective was to describe the microbiological and clinical outcomes associated with β-lactam therapeutic drug management.

DESIGN: Electronic Medical Record Review.

SETTING: A 189-bed, freestanding children's tertiary care teaching hospital in Philadelphia, PA.

PATIENTS: Patients admitted to the PICU from September 1, 2014, to May 31, 2017, with sepsis and those receiving extracorporal therapy with either extracorporeal membrane oxygenation or continuous renal replacement therapy that had routine β-lactam therapeutic drug management.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Eighty-two patients were in the total cohort and 23 patients in the infected cohort accounting for 248 samples for therapeutic drug management analysis. The median age was 1 year (range, 4 d to 18 yr) with a mean weight of 19.7 ± 22.3 kg (range, 2.7-116 kg). Twenty-three patients (28%) had growth of an identified pathogen from a normally sterile site. Seventy-eight of 82 patients (95%) had subtherapeutic anti-infective concentrations and did not attain the primary pharmacodynamic endpoint. All patients in the infected cohort achieved a microbiological response, and 22 of 23 (95.7%) had a positive clinical response.

CONCLUSIONS: Overall, 95% of patients had subtherapeutic anti-infective concentrations and did not achieve the requisite pharmacodynamic exposure with current pediatric dosing recommendations. All patients achieved a microbiological response, and 95.7% achieved clinical response with active β-lactam therapeutic drug management. These data suggest β-lactam therapeutic drug management is a potentially valuable intervention to optimize anti-infective pharmacokinetics and the pharmacodynamic exposure. Further, these data also suggest the need for additional research in specific pediatric populations and assessing clinical outcomes associated with β-lactam therapeutic drug management in a larger cohort of pediatric patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Cies JJ, Moore WS, Enache A, et al. β-lactam Therapeutic Drug Management in the PICU. Crit Care Med. 2018. PMID: 29112080. doi:10.1097/CCM.0000000000002817

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。